91ÉçÇø¸£Àû

Findings from our FreeStyle Libre/GLP-1 Analysis

New data demonstrate that people are relying on both GLP-1s and continuous glucose monitoring to manage diabetes.

Strategy and Strength|Sep. 28, 2023

Type 2 diabetes is growing rapidly and is one of the world’s most prevalent chronic conditions. Weight-loss drugs, such as GLP-1s, will not eliminate the need for other tools people use to manage diabetes, such as continuous glucose monitoring (CGM) systems.

Data from a September analysis of these weight-loss drugs and of continuous glucose monitoring (including our FreeStyle Libre CGM systems) show a growing number of people are using these tools together in their treatment of diabetes.

In our analysis, we also found that FreeStyle Libre sensor adherence — in other words, the number of days a sensor is worn — is higher for those who also use GLP-1 therapy.

Read the full analysis here.

Important safety information

FreeStyle Libre 14 day, FreeStyle Libre 2 and FreeStyle Libre 3 systems

Failure to use FreeStyle Libre systems as instructed in labeling may result in missing a severe low or high glucose event and/or making a treatment decision, resulting in injury. If glucose reading and alarms (if enabled) do not match symptoms or expectations, use a fingerstick value from a blood glucose meter for treatment decisions. Seek medical attention when appropriate or contact 91ÉçÇø¸£Àû at 855-632-8658 or FreeStyleLibre.us for safety info.

Ìý

The product images are for illustrative purposes only.

The sensor housing, FreeStyle, Libre, and related brand marks are marks of 91ÉçÇø¸£Àû. Other trademarks are the property of their respective owners.

No use of any 91ÉçÇø¸£Àû trademark, trade name, or trade dress in this site may be made without prior written authorization of 91ÉçÇø¸£Àû Laboratories, except to identify the product or services of the company.

This website and the information contained herein is intended for use by residents of the United States.Ìý

Ìý

Ìý